#ASCO21: Adaptimmune gives first glimpse at pivotal data for what they hope will be first approved TCR
Six years after Adaptimmune hauled what at the time was one of biotech’s largest-ever IPOs, CEO Adrian Rawcliffe thinks they’re finally on track to get the first TCR therapy over the finish line.
Adaptimmune released new data Wednesday showing their TCR therapy, known as afami-cel, shrunk the tumors of 13 of the 33 evaluable second-line sarcoma patients, including two patients whose tumors melted entirely. That was good for a 39% objective response rate — which Rawcliffe characterized as a major advance. He contrasted it with the handful of other treatments available for these patients, such as Votrient, a chemotherapy with a response rate in the single digits or low teens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.